CoChat

Baseline Factors Associated With Glycemic Control and Weight Loss When Exenatide Twice Daily Is Added to Optimized Insulin Glargine in Patients With Type 2 Diabetes

Open access
Rosenstock, Julio, Shenouda, Sylvia K., Bergenstal, Richard M., Buse, John B., Glass, Leonard C., Heilmann, Cory R., Kwan, Anita Y.M., MacConell, Leigh A., Hoogwerf, Byron James · 2012 · Diabetes Care
Cited by 66

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: To determine variables associated with glycemic and body weight responses when adding exenatide to basal insulin–treated type 2 diabetes. RESEARCH DESIGN AND METHODS: Exploratory subgroup analyses based on baseline A1C, disease duration, and BMI of a 30-week study comparing exenatide twice daily to placebo, added to optimized insulin glargine (intent-to-treat analysis: 137 exenatide; 122 placebo). RESULTS: Exenatide participants had greater A1C reductions compared with optimized insulin glargine alone, irrespective of baseline A1C (P < 0.001). Exenatide participants with longer diabetes duration and those with lower BMI had greater A1C reductions (P < 0.01). Exenatide participants lost more weight, regardless of baseline A1C or BMI (P < 0.05). Exenatide participants with longer diabetes duration lost the most weight (P < 0.001). CONCLUSIONS: Exenatide added to optimized basal insulin was associated with improved glycemic control and weight loss, irrespective of baseline A1C, diabetes duration, and BMI. Changes were evident in modestly obese patients and in those with longer diabetes duration.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc11-1434

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 66

Metadata

Authors
Rosenstock, J., Shenouda, S. K., Bergenstal, R. M., Buse, J. B., Glass, L. C., Heilmann, C. R., Kwan, A. Y. M., MacConell, L. A., & Hoogwerf, B. J.
Venue
Diabetes Care
Published
2012-04-11
Volume
35
Issue
5
Pages
955-958
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W2148058633
Cited by
66
References
3
FWCI
6.67
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Baseline Factors Associated With Glycemic Control and Weight Loss When Exenatide Twice Daily Is Added to Optimized Insulin Glargine in Patients With Type 2 Diabetes. https://app.cochat.ai/papers/10.2337/dc11-1434
The paper
Rosenstock, J., Shenouda, S. K., Bergenstal, R. M., Buse, J. B., Glass, L. C., Heilmann, C. R., Kwan, A. Y. M., MacConell, L. A., & Hoogwerf, B. J. (2012). Baseline Factors Associated With Glycemic Control and Weight Loss When Exenatide Twice Daily Is Added to Optimized Insulin Glargine in Patients With Type 2 Diabetes. Diabetes Care. https://doi.org/10.2337/dc11-1434

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.